Active ingredients: liothyronine
What it is used for
INDICATIONS AS AT 01 JAN 1991 : Tertroxin is indicated in the treatment of : coma due to myxoedema; management of severe thyroid deficiency; hypothyroid states arising in treatment of thyrotoxicosis. Tertroxin may be preferred for treating severe and acute hypothyroid states because of its rapid and more potent effect but thyroxine sodium is normally the drug of choice for routine replacement therapy. Tertroxin can also be used therapeutically in the treatment of thyrotoxicosis as an adjunct to carbimazole in order to prevent sub-clinical hypothyroidism developing during treatment.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Light
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
White, biconvex tablets with break-line on one face and plain on the other face
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2021. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient liothyronine
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems